Clinical significance of PM-Scl antibody detection in systemic scleroderma
10.3969/j.issn.1673-4130.2015.17.030
- VernacularTitle:系统性硬化症患者P M-S cl抗体检测的临床意义
- Author:
Yang YE
;
Xiaomei GAO
;
Nanping YANG
- Publication Type:Journal Article
- Keywords:
scleroderma,systemic;
anti-polymyositis-scleroderma antibody;
anti-Scl-70 antibody;
anti-centromere antibody
- From:
International Journal of Laboratory Medicine
2015;(17):2526-2528
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze and discuss the expression of serum polymyositis‐scleroderma(PM‐Scl) antibody and its clinical significance in patients with systemic scleroderma(SSc) .Methods 315 hospitalized patients diagnosed with scleroderma by typical clinical manifestations or skin pathology from 2009 to 2012 were enrolled in the study .All patients were grouped into PM‐Scl antibody positive(PM‐Scl + ) group(90 cases) ,Scl‐70 antibody positive(Scl‐70+ ) group(70 cases) ,anti‐centromere antibody positive( ACA+ ) group(75 cases) and antibody negative group(80 cases) according to autoantibody spectrum .The severity of skin and visceral damage among all the groups were analyzed and compared .Results Patients in PM‐Scl+ group were characterized with different clinical manifestations .Compared with the other 3 groups ,the incidence of myositis in PM‐Scl+ group was significantly higher( all P< 0 .05) ;patients in Scl‐70+ group had higher incidence of visceral organ damage than PM‐Scl+ group(all P < 0 .05) .The incidence of skin lesions ,Raynaud′s phenomenon and capillary expansion in ACA+ group were higher than that of PM‐Scl+ ,while the incidence of interstitial lung disease ,heart disease and kidney disease were lower(all P< 0 .05) .Conclusion It is helpful for clinicists′ further understanding of common autoantibodies in Ssc patients and making correct assessment of the disease through analyzing the expression of PM‐Scl antibody .
